I’m sorry but $15 is way way to conservative after a Covid EUA. All vials will be immediate sold. Way way to much upside for millions of additional vials to be produced and sold in advance of even manufacturing them. $15 would give market cap just above $8 billion currently at 2.7 billion. 2021 sales alone could top what your saying you think will be share price. Using conservative PE ratio of other biotechs we should see share price settling somewhere closer to $30-$40 with it peaking even higher. If you factor in that this is heavily shorted and that companies often times go multiples higher than they are worth than we could see a huge run up. I will be way more surprised if we don’t reach $35+ than if we only hit $15